Hale G - Search Results

1

Systematic analysis of Fc mutations designed to enhance binding to Fc-gamma receptors.

Hale G, Davy AD, Wilkinson I. Hale G, et al. MAbs. 2024 Jan-Dec;16(1):2406539. doi: 10.1080/19420862.2024.2406539. Epub 2024 Sep 22. MAbs. 2024. PMID: 39306747 Free PMC article.

2

Fc-engineered antibodies with immune effector functions completely abolished.

Wilkinson I, Anderson S, Fry J, Julien LA, Neville D, Qureshi O, Watts G, Hale G. Wilkinson I, et al. Among authors: hale g. PLoS One. 2021 Dec 21;16(12):e0260954. doi: 10.1371/journal.pone.0260954. eCollection 2021. PLoS One. 2021. PMID: 34932587 Free PMC article.

3

Systematic analysis of the varied designs of 819 therapeutic antibodies and Fc fusion proteins assigned international nonproprietary names.

Wilkinson I, Hale G. Wilkinson I, et al. Among authors: hale g. MAbs. 2022 Jan-Dec;14(1):2123299. doi: 10.1080/19420862.2022.2123299. MAbs. 2022. PMID: 36109838 Free PMC article.

4

Systematic analysis of Fc mutations designed to reduce binding to Fc-gamma receptors.

Hale G, De Vos J, Davy AD, Sandra K, Wilkinson I. Hale G, et al. MAbs. 2024 Jan-Dec;16(1):2402701. doi: 10.1080/19420862.2024.2402701. Epub 2024 Sep 15. MAbs. 2024. PMID: 39279104 Free PMC article.

5

Living in LALA land? Forty years of attenuating Fc effector functions.

Hale G. Hale G. Immunol Rev. 2024 Nov;328(1):422-437. doi: 10.1111/imr.13379. Epub 2024 Aug 19. Immunol Rev. 2024. PMID: 39158044 Free PMC article. Review.

6

Methods to measure the binding of therapeutic monoclonal antibodies to the human Fc receptor FcγRIII (CD16) using real time kinetic analysis and flow cytometry.

Harrison A, Liu Z, Makweche S, Maskell K, Qi H, Hale G. Harrison A, et al. Among authors: hale g. J Pharm Biomed Anal. 2012 Apr 7;63:23-8. doi: 10.1016/j.jpba.2012.01.029. Epub 2012 Jan 30. J Pharm Biomed Anal. 2012. PMID: 22366323

7

Dry-compression packing of hydroxyapatite nanoparticles within a flat cuboid chromatography device and its use for fast protein separation.

Ghosh R, Hale G, Durocher Y, Gatt P. Ghosh R, et al. Among authors: hale g. J Chromatogr A. 2022 Mar 29;1667:462881. doi: 10.1016/j.chroma.2022.462881. Epub 2022 Feb 4. J Chromatogr A. 2022. PMID: 35149414

8

Preclinical development of monoclonal antibodies: considerations for the use of non-human primates.

Chapman K, Pullen N, Coney L, Dempster M, Andrews L, Bajramovic J, Baldrick P, Buckley L, Jacobs A, Hale G, Green C, Ragan I, Robinson V. Chapman K, et al. Among authors: hale g. MAbs. 2009 Sep-Oct;1(5):505-16. doi: 10.4161/mabs.1.5.9676. Epub 2009 Sep 30. MAbs. 2009. PMID: 20065651 Free PMC article.

9

Pharmacokinetics and antibody responses to the CD3 antibody otelixizumab used in the treatment of type 1 diabetes.

Hale G, Rebello P, Al Bakir I, Bolam E, Wiczling P, Jusko WJ, Vandemeulebroucke E, Keymeulen B, Mathieu C, Ziegler AG, Chatenoud L, Waldmann H. Hale G, et al. J Clin Pharmacol. 2010 Nov;50(11):1238-48. doi: 10.1177/0091270009356299. Epub 2010 Feb 10. J Clin Pharmacol. 2010. PMID: 20147616 Clinical Trial.

10

Recent developments in humanized MAbs for immunotherapy: a personal tribute to Dr. Martin Lockwood.

Hale G. Hale G. Transfus Sci. 1999 Dec;21(3):181-4. Transfus Sci. 1999. PMID: 10848438 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

755 results

Search Page

Filters